RecruitingPhase 4NCT06726395
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
Randomized Controlled Clinical Trial Comparing Treatment With Cloxacillin Versus Benzylpenicillin in Bacteraemia Caused by Penicillin-susceptible Staphylococcus Aureus (PSSA)
Sponsor
Region Skane
Enrollment
420 participants
Start Date
Mar 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Aged ≥18 with penicillin susceptible S. aureus bacteraemia (PSSA), and able to provide written informed consent.
Exclusion Criteria8
- allergy to penicillin,
- inability to give informed consent,
- concomitant growth of other clinically significant bacteria in blood cultures
- neutropenia
- ≥ 96h with prior antibiotics
- When the per oral follow up medication can not be flukloxacillin or penicillinV/Amoxicillin (ie prosthetic joint infection)
- Patients in terminal palliation, where death is expected within 7 days.
- Where the treating physician believes cloxacillin is not a first-line treatment.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPenicillin G_1200mg
benzylpenicillin preferred dosing 1gx4
DRUGcloxacillin
cloxacillin 2gx4
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06726395